Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
28 févr. 2024 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
12 févr. 2024 07h00 HE
|
Optimi Health Corp.
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
Optimi Announces Non-Brokered Private Placement
08 févr. 2024 07h30 HE
|
Optimi Health Corp.
Optimi Announces Non-Brokered Private Placement
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
06 févr. 2024 07h30 HE
|
Optimi Health Corp.
Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
19 janv. 2024 07h30 HE
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
03 janv. 2024 07h30 HE
|
Optimi Health Corp.
Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor used in the chemical synthesis of MDMA.
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
07 déc. 2023 07h30 HE
|
Optimi Health Corp.
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
28 nov. 2023 07h42 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
Optimi Health Resolves Dispute
10 nov. 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company") is pleased to announce the successful resolution...
Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
07 nov. 2023 07h30 HE
|
Optimi Health Corp.
Optimi Health Introduces New Chief Science Officer Dr. Preston A. Chase.